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Abstract
Anti-angiogenic therapy reduces both plaque growth and intimal neovascularization in apolipoprotein-E-deficient mice (apoE−/−). Vascular
endothelial growth factor (VEGF) has been suggested as playing a role in the development of atherosclerosis. We examined the hypothesis
that VEGF and VEGF receptor-2 (VEGFR-2) expression is upregulated in apoE−/− and, since it could be driven by oxidative stress, tested
whether dietary supplementation with vitamins C and E could downregulate it.
Two-month-old apoE−/− received vitamin C combined with- or-tocopherol for 4 weeks. Aortic VEGF and VEGFR-2 expression were
measured by RT-qPCR and western blot.
ApoE−/− showed significantly higher expression of aortic VEGF and VEGFR-2 mRNA (P < 0.001) and protein (P < 0.001) than
wild-type mice, as well as increased plasma VEGF (P < 0.001). Vitamin C and -tocopherol significantly reduced aortic VEGF and
VEGFR-2 expression in apoE−/− (P < 0.001), circulating VEGF (P < 0.01) and plasma lipid peroxidation (P < 0.01). apoE−/− receiving
vitamin C and -tocopherol showed diminished lipid peroxidation and VEGFR-2, but only partial reduction of VEGF expression.
These data demonstrate that augmented VEGF and VEGFR-2 expression in apoE−/− vasculature can be downregulated by vitamins C
and E, at least partially through oxidative stress reduction. This novel mechanism could contribute to explaining the beneficial effects of
antioxidant vitamins in experimental atherosclerosis.
© 2003 Elsevier Ireland Ltd. All rights reserved.
Keywords: VEGF; VEGFR-2; Hypercholesterolemia; Ascorbic acid; Tocopherol
1. Introduction
Vascular endothelial growth factor (VEGF), the main
agent responsible for angiogenesis and vascular permeabil-
ity, is a 45 kDa glycoprotein secreted in the vascular wall by
endothelial and smooth muscle cells. It has also been im-
plicated in the maintenance of endothelial integrity, partly
through upregulation of endothelial nitric oxide synthase
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expression [1]. VEGF expression is regulated mainly by
hypoxia [2], oxidative stress [3] and nitric oxide [4,5]. The
biological effects of VEGF are mediated mainly by two
tyrosin kinase receptors: VEGFR-1 (Flt-1) and VEGFR-2
(flk-1/KDR). VEGFR-2 is essential for vasculogenesis,
angiogenesis and hematopoiesis [6], and mediates VEGF
antiapoptotic effects in endothelium [7].
Despite these functions, VEGF could also be consid-
ered a pro-atherogenic factor, because its administration
increases the rate and degree of atherosclerotic plaque
formation in apo-E/apo-B100 deficient mice and in hy-
percholesterolemic rabbits [8]. Moreover, VEGF has been
found to be upregulated in human coronary atheroscle-
rotic lesions but not in normal coronary segments [9].
Although the mechanism by which VEGF induces plaque
formation has not been established, it has been suggested
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that new vessel formation causes plaque progression [8].
The administration of the anti-angiogenic drug endo-
statin to apolipoprotein-E-deficient mice (apoE−/−), a
well-characterized model of atherosclerosis, reduces both
plaque growth and intimal neovascularization, providing
evidence that neovascularization is required for atheroscle-
rosis plaque development [10].
Interestingly, the apoE−/−murine model of hypercholes-
terolemia is characterized by increased oxidative stress [11]
and reduced nitric oxide bioavailability [12], two mecha-
nisms known to contribute to atherosclerotic plaque develop-
ment and also involved in the regulation of VEGF expression
[3,4]. Increased VEGF levels have been reported in plasma
from hypercholesterolemic individuals [13] and in coronary
arteries from hypercholesterolemic pigs [14]. Moreover, it
has been shown that oxidized LDL, a key molecule in the
atherosclerotic process, can upregulate VEGF expression in
macrophages and endothelial cells, at least partially through
the activation of PPAR [15]. In this context, assuming that
VEGF acting through VEGFR-2 can be at least one of the
factors responsible for the angiogenic processes required for
atherosclerosis plaque development, we hypothesized that
either of them could be upregulated in the vascular wall of
apoE−/− mice.
A potential role of antioxidant vitamins in cardiovascular
disease prevention has been proposed, based on the essen-
tial role of lipoproteins oxidation in the initiation and pro-
gression of atherosclerotic lesions. To date, there is no clear
evidence from clinical trials that antioxidants provided by
dietary intake or in the form of vitamin supplements can re-
duce the risk of atherosclerosis [16,17]. However, a number
of studies in different animal models have considered the
potential for different dietary antioxidants to help prevent
development and progression of atherosclerosis, and most
of the experimental evidence helps substantiate this hypoth-
esis [18,19]. Particularly, -tocopherol has been shown to
decrease lipid peroxidation and atherosclerosis in apoE−/−
[11].
Since VEGF and/or VEGFR-2 could be upregulated in
apoE−/− vasculature as a consequence of increased oxida-
tive stress, we investigated whether dietary supplementation
with vitamin C and -tocopherol could downregulate VEGF
and VEGFR-2 expression in this animal model. The com-
bination of vitamin C and -tocopherol was also studied to
elucidate whether antioxidant mechanisms can fully account
for the effects of vitamin supplementation.
2. Methods
2.1. Mice
C57BL/6 wild type (WT) mice and apoE−/− were pro-
cured from the colony at CIFA (GLP accredited center
at the University of Navarra) animal facilities, originat-
ing from breeders obtained from Center for Transgene
Technology and Gene Therapy (Flanders Interuniversity
Institute for Biotechnology, Leuven). The investigation
was performed in accordance with the European Com-
munity guidelines for animal ethical care and use of lab-
oratory animals (Directive 86/609), and was approved
by the University of Navarra Animal Research Review
Committee.
Two-month-old male wild type and apoE−/− mice
fed a standard rodent diet (Harlan Teklad 9605) were di-
vided into four groups (n = 11): non-treated wild type
and apoE−/−, and vitamins C and E supplemented mice
(WT-CE, apoE−/−CE). Ascorbic acid (120 mg kg−1 per
day) and -tocopherol (210 mg kg−1 per day) were given in
drinking water. An additional group of apoE−/− mice re-
ceived 120 mg kg−1 per day ascorbic acid and 210 mg kg−1
per day -tocopherol (n = 5, apoE−/−CE). Two hun-
dred micromolar stock solutions of -tocopherol and
-tocopherol in ethanol were prepared to facilitate final
dilutions in water. -tocopherol was generously provided
by Dr. Christine Gartner (Cognis, Germany). Daily liquid
intake, measured by weighing water bottles, was similar in
mice from each experimental group (5 ml per animal per
day). After 4 weeks of treatment, animals were sacrificed
and blood was drawn by cardiac puncture.
Plasma total cholesterol and tryglicerides were deter-
mined by colorometric assay (Sigma). Plasma concentration
of thiobarbituric acid-reactive substances (TBARS) was
measured, as indicator of lipid peroxidation [20]. Aorta was
removed, dissected free of interstitial tissue with the help of
a surgical microscope (Zeiss OPMI 6CR/S3), immediately
frozen and stored at −80 ◦C. Tocopherol concentration in
plasma was measured by high performance liquid chro-
matography [19].
2.2. RNA isolation and real-time quantitative RT-PCR
Total RNA was extracted from each aorta with TRIzol
(Invitrogene) and quantified with ultraviolet spectroscopy.
Total RNA (5g) was reverse-transcribed with oligo (dT)
primers with M-MLV reverse transcriptase (Invitrogene), in
the presence of SuperRNase In (Ambion).
Three hundred nanograms of reverse-transcribed RNA
was primed with oligonucleotides specific for VEGF
(5′-GAGACCCTGGTGGACATC-3′ and 5′-TTTCTTTGG-
TCTGCATTC-3′), VEGFR-2 (5′-GACTGTGGCGAAGTG-
TTTTTGA-3′ and 5′-GTGCAGGGGAGGGTTGGCGTA-
G-3′) and -actin (5′-GCCTTCCTTCTTGGGTATGG-3′
and 5′-ACGCAGCTCAGTAACAGTCC-3′). PCR was per-
formed as previously described (95 ◦C for 10 min and run
for 40 cycles at 95 ◦C for 15 s and 60 ◦C for 1 min) with
SYBR Green PCR Master Mix (Applied Biosystems) on the
ABI PRISM 5700 Detection System (Applied Biosystems)
[21]. Potential genomic DNA contamination was excluded
by using intron-encompassing primers. All samples were
assayed in triplicate and normalized on the basis of their
-actin content.
B. Nespereira et al. / Atherosclerosis 171 (2003) 67–73 69
2.3. Protein extraction, electrophoresis and western
blotting
Following TRIzol manufacturer’s instructions, protein
was extracted from aortic homogenates after RNA isolation.
Protein concentration was determined according to Brad-
ford [22]. VEGF was quantified in murine plasma and aorta
by western blotting: plasma samples (diluted 1:20 in saline)
and aortic homogenates (10g total protein) were subjected
to 12% SDS-PAGE, electroblotted onto nitrocellulose mem-
branes and probed with anti-VEGF (1:1000, sc7269, Santa
Cruz Biotechnologies), followed by a peroxidase-linked
sheep anti-mouse IgG (1:5000, Amersham Biosciences).
Blots were developed by enhanced chemiluminescence
according to the manufacturer’s instructions (ECL, Amer-
sham Biosciences). Aortic expression of VEGFR-2 was as-
sessed similarly, subjected to 6% SDS-PAGE, probed with
anti-VEGFR-2 (1:1000, sc6251, Santa Cruz Biotechnolo-
gies) and developed by enhanced chemiluminescence (ECL
Plus, Amersham Biosciences). Even loading was verified
by Ponceau red staining.
2.4. Statistical methods
Data are presented as mean ± standard deviation. Anal-
ysis of variance (ANOVA) or Kruskal–Wallis test was ap-
plied to assess differences between treatment groups. After
a significant ANOVA or Kruskal–Wallis, comparisons were
made with Bonferroni posthoc or Mann–Whitney test, re-
spectively. A value of P < 0.05 was accepted as statistically
significant.
3. Results
3.1. Cholesterol, triglyceride and lipid peroxidation in
murine plasma
Table 1 shows the general characteristics of the different
animal groups. Plasma total cholesterol and triglycerides
were significantly higher in apoE−/− than in WT mice
Table 1
Plasmatic parameters of the different animal groups at the time of the sacrificeb
Total cholesterol
(mmol/l)
Triglycerides
(mmol/l)
Tocopherol
(mol/l)
Tocopherol/cholesterol
(mol/mmol)
TBARS
(mmol MDA/l)
WT (n = 11) 1.71 ± 0.34 0.60 ± 0.26 35.3 ± 13.7 18.1 ± 7.1 1.18 ± 0.36
WT-CE (n = 11) 1.78 ± 0.31 0.53 ± 0.12 94.9 ± 28.3∗∗∗ 50.2 ± 13.2∗∗∗ 0.92 ± 0.52
apoE−/− (n = 11) 18.78 ± 4.04∗∗∗ 1.16 ± 0.34∗∗∗ 36.8 ± 12.5 1.9 ± 0.7∗∗∗ 1.76 ± 0.45∗∗∗
apoE−/−CE (n = 11) 14.74 ± 3.78∗∗∗†† 1.04 ± 0.15∗∗∗ 103.4 ± 34.5††† 7.4 ± 2.7∗∗†† 1.25 ± 0.39††
apoE−/−CE (n = 5) 18.83 ± 2.38∗∗∗ 0.88 ± 0.10∗∗∗ 100.7 ± 46.7†† 7.5 ± 3.5∗∗†† 1.14 ± 0.16††
Plasma total cholesterol (mmol/l), triglycerides (mmol/l), tocopherol (mol/l) and TBARS (mmol MDA/l) are shown. Statistically significant differences
from WT are marked as ∗∗(P < 0.01), ∗∗∗(P < 0.001), and from apoE−/− as ††(P < 0.01, †††(P < 0.001).
b WT: wild type; WT-CE: supplemented with vitamins C and E; apoE−/−: apoE-deficient; apoE−/−CE: apoE−/− supplemented with vitamin C and
apoE−/−CE: -tocopherol or -tocopherol.
(P < 0.001 in both cases). Both types of mice presented
similar plasma tocopherol concentration, although toco-
pherol/cholesterol ratio was markedly reduced in apoE−/−
(P < 0.001), in agreement with the increased TBARS
(P < 0.01), in comparison with WT mice.
3.2. Vascular VEGF and VEGFR-2 expression in
apoE−/− mice
Vascular expression of VEGF mRNA in apoE−/− was
nearly five times higher than in WT group (P < 0.001;
Fig. 1A). As shown in Fig. 1B, the observed mRNA increase
was accompanied by a higher VEGF protein content in the
vessel wall (P < 0.001).
Since VEGFR-2 plays a leading role in VEGF-induced
angiogenesis, we analyzed vascular VEGFR-2 expression in
the same in vivo model. As expected, a threefold increase
in VEGFR-2 mRNA was observed in apoE−/− mice as
compared with WT (P < 0.001; Fig. 2A), and a higher
VEGFR-2 protein content in the vessel wall could also be
demonstrated (P < 0.001; Fig. 2B).
Relative VEGF levels in plasma were analyzed by west-
ern blotting to determine if they would reflect the observed
changes in the vascular wall. VEGF plasma levels were sig-
nificantly higher in apoE−/− rather than WT mice (P <
0.001; Fig. 3).
3.3. Effect of vitamin C and α-tocopherol on
VEGF and VEGFR-2
Compliance with the vitamins supplementation was ev-
ident, as plasma tocopherol levels in the groups receiving
vitamin E increased to above the levels in non-supplemented
mice (P < 0.001), and significantly reduced apoE−/−
plasma TBARS (P < 0.01) down to WT levels, even
though tocopherol/cholesterol ratio was still lower than WT
(P < 0.01; Table 1). While plasma total cholesterol and
triglycerides remained unchanged after treatment in WT
mice, a marginal reduction in total cholesterol levels was
observed in treated apoE−/− (P < 0.01), the levels still
remaining eightfold higher than in WT.
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Fig. 1. Changes in vascular VEGF expression (mRNA and protein),
reported as percentage increase with respect to untreated wild type
(WT) mice. (A) VEGF mRNA, assessed by RT-qPCR and corrected
by -actin mRNA content, is increased in apoE−/− mice. Vitamin C
+ -tocopherol treatment (apoE−/−CE) reduces it significantly, but vita-
min C + -tocopherol (apoE−/−CE) only achieves a partial reduction.
(B) Augmented VEGF protein in apoE−/−, assessed by western blot
(densitometric analysis and representative blot showing the 25 kDa VEGF
monomer), is significantly reduced in apoE−/−CE and apoE−/−CE.
Bars represent the mean ± S.D. for all the animals in the experimen-
tal group (size indicated below x-axis). Statistically significant differ-
ences from WT are marked as ∗∗∗(P < 0.001), and from apoE−/− as
†(P < 0.05), †††(P < 0.001).
Interestingly, the combination of vitamin C and -
tocopherol significantly decreased aortic VEGF and
VEGFR-2 expression in apoE−/−, both at mRNA and
protein level (P < 0.001 in all cases; Figs. 1 and 2), but
it did not substantially modify their expression in WT. It
only showed a marginal reduction in VEGF and VEGFR-2
mRNA expression remaining unchanged.
As found in the vessel wall, vitamin C and -tocopherol
also markedly reduced VEGF plasma levels in apoE−/−
mice (Fig. 3, P < 0.01), as compared with WT.
3.4. Effect of vitamins C and β-tocopherol on
VEGF and VEGFR-2
Dietary supplementation of apoE−/− mice with ascor-
bic acid and -tocopherol was equally efficient to increase
plasma tocopherol concentration (P < 0.01) and to reduce
Fig. 2. Vascular VEGFR-2 expression, reported as percentage increase
with respect to untreated wild type (WT) mice. (A) VEGFR-2 mRNA,
assessed by RT-PCR and corrected by -actin mRNA content, is increased
in apoE−/− mice. Vitamin C combined with -tocopherol (apoE−/−CE)
or -tocopherol (apoE−/−CE) reduces it significantly. (B) Augmented
VEGFR-2 protein in apoE−/−, assessed by western blot (densitometric
analysis and representative blot), is significantly reduced in apoE−/−CE
and apoE−/−CE. Bars represent the mean±S.D. for all the animals in the
experimental group (size indicated below x-axis). Statistically significant
differences from WT are marked as ∗∗∗(P < 0.001), and from apoE−/−
as †††(P < 0.001).
plasma TBARS (P < 0.01), the tocopherol/cholesterol ratio
being still lower than WT (P < 0.01; Table 1). No mod-
ifications were observed in total cholesterol or triglyceride
concentrations.
In contrast to mice receiving vitamin C and -tocopherol,
treatment of apoE−/−with vitamin C and -tocopherol only
achieved a partial, although significant, reduction (20%) in
vascular VEGF mRNA and protein expression (P < 0.05,
Fig. 1). However, no differences between the effect of  and
-tocopherol were observed in plasma VEGF (Fig. 3) or in
vascular VEGFR-2 mRNA and protein levels (Fig. 2).
No deleterious effects were observed in any of the animals
receiving the different vitamin treatments.
4. Discussion
We report herein that vitamins C and E markedly re-
duce the expression of VEGF and its endothelial receptor
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Fig. 3. Relative VEGF concentration in plasma, assessed by western
blotting, and reported as percentage increase with respect to untreated wild
type (WT) animals. Increased circulating VEGF in apoE−/− mice can
be reduced by vitamin C + -tocopherol (apoE−/−CE) or -tocopherol
(apoE−/−CE) treatment. Lower panel: representative immunoblot of
murine plasma. Bars represent the mean± S.D. for all the animals in the
experimental group (size indicated below x-axis). Statistically significant
differences from WT are marked as ∗∗∗P < 0.001, and from apoE−/−
as ††P < 0.01.
VEGFR-2 in a murine model of atherosclerosis, represent-
ing a novel effect of these compounds. In this study, we
demonstrate a significant increase of VEGF and VEGFR-2
in the aorta of apoE−/− mice, as compared to WT. Further-
more, to our knowledge, this is the first report showing that
dietary supplementation with vitamins C and E significantly
reduces vascular expression of VEGF and VEGFR-2 in this
experimental model.
VEGF has a dual role in vascular homeostasis: it is
not only the principal agent responsible for angiogenesis,
vascular permeability and maintenance of endothelial in-
tegrity, but it also favors the progression and growth of
the atherosclerotic plaque [8]. VEGF and VEGFR-2 ex-
pression were measured in apoE−/− mice, an accepted
model of atherosclerosis showing high cholesterol concen-
tration, increased lipid peroxidation [11] and low nitric
oxide bioavailability [12]. We found higher levels of aorta
and plasma VEGF in apoE−/− than in WT, in agreement
with previous observations in the coronary arteries of hy-
percholesterolemic pigs [14], as well as in the plasma of
hypercholesterolemic patients [13]. Moreover, increased
vascular VEGF was accompanied by a marked upregula-
tion in VEGFR-2 expression, a novel finding not described
previously in hypercholesterolemia.
Upregulation of VEGF and VEGFR-2 in the vessel wall
could account for the increased vascular permeability [23]
and enhanced vasa vasorum neovascularization observed
in experimental models of hypercholesterolemia [24]. Al-
though the mechanism by which hypercholesterolemia may
induce VEGF upregulation in the vessel wall remains un-
clear, possible pathophysiological stimuli include hypoxia
[14], oxidative stress [3] and low NO bioavailability [4].
Moreover, VEGF upregulation has been proposed to be a
non-specific stress-induced vascular response in the adult
organism [25], or to constitute a vascular homeostatic
mechanism for compensating endothelial dysfunction [1].
Independently of the mechanism responsible, sustained
vascular VEGF overexpression could contribute to the
atherosclerotic process by favoring lipoprotein infiltration
through increased vascular permeability [23], inflammation
[26] and angiogenesis [8]. The anti-atherosclerotic effect of
the angiogenesis inhibitors endostatin and TNP-470 in the
apoE−/− [10] would support this hypothesis.
Dietary supplementation of apoE−/− mice with ascorbic
acid and -tocopherol significantly decreased both VEGF
and VEGFR-2 expression, as well as plasma TBARS, while
it augmented the tocopherol/cholesterol ratio. It can be
speculated that the observed downregulation could be due to
their antioxidant activity and/or the protein kinase C (PKC)
inhibitory activity of -tocopherol. A similar vitamin E
dose, higher than that used therapeutically in humans, has
been proved to reduce oxidative stress and atherosclerosis
in apoE−/− mice [11], and vitamin C was administered
to ensure -tocopherol regeneration from -tocopheroxy
radical, thereby preventing vitamin E pro-oxidant activity
and tocopherol-mediated peroxidation [27]. In spite of the
high dose of vitamin E administered, the threefold increase
observed in plasma tocopherol is not far away from the
twofold increase reported in several human trials studying
vitamin E supplementation.
The combination of ascorbic acid and -tocopherol, an
equally strong antioxidant in comparison to -tocopherol but
lacking other biological properties present in -tocopherol
PKC inhibitory and antiproliferative activities) [28] par-
tially decreased VEGF expression, suggesting that the
reduction of oxidative stress is not the only mechanism in-
volved. Since augmented PKC activity has been shown in
apoE−/− [29] and PKC activation can upregulate VEGF
expression [4], it is conceivable that the observed in vivo
effect of -tocopherol on VEGF expression is due to both
antioxidant and PKC inhibitory effects. It could be also
argued that differences in the intestinal absorption, trans-
lated into different bioavailabilities for  and -tocopherol,
could account for the observed effects on VEGF expression.
However, no differences were observed in plasma toco-
pherol between vitamin-treated apoE−/− mice, and the fact
that both treatments similarly reduced vascular VEGFR-2
expression suggests that antioxidant mechanisms are fully
responsible for VEGFR-2 downregulation while only ac-
counting for partial VEGF reduction. This point would re-
quire further confirmation by measuring local production of
reactive oxygen species and/or lipid peroxidation markers
more specific and sensitive than TBARS (i.e. isoprostanes).
Interestingly, both treatments also achieved a similar sig-
nificant reduction in circulating VEGF levels. Although the
pathophysiological meaning of the observed changes is not
clear yet [13], given that systemic VEGF levels may not
strictly reflect changes occurring in the vessel wall, its de-
termination could become a valuable tool to investigate the
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relationship between hypercholesterolemia, atherosclerosis
and angiogenesis, together with its pharmacological modu-
lation.
Since VEGF seems to be necessary in the development
of atherosclerosis [26] and treatment with angiogenesis
inhibitors reduces both plaque growth and intimal neovascu-
larization in apoE−/− mice [10], the observed downregula-
tion of VEGF and VEGFR-2 expression by the combination
of vitamins C and E would be an additional mechanism
by which these agents could prevent and limit atheroscle-
rotic plaque progression [18,30]. Further studies should be
conducted in a well-defined human hypercholesterolemic
population to assess whether the effects of vitamins C and
E supplementation observed in mice can be reproduced also
in humans.
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